



**HAL**  
open science

## Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm

N. van Geel, R. Speeckaert, Alain Taïeb, K. Ezzedine, H.W. Lim, A.G. Pandya, T. Passeron, A. Wolkerstorfer, M. Abdallah, A. Alomar, et al.

### ► To cite this version:

N. van Geel, R. Speeckaert, Alain Taïeb, K. Ezzedine, H.W. Lim, et al.. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm. *Journal of the European Academy of Dermatology and Venereology*, 2023, 37 (11), pp.2173-2184. 10.1111/jdv.19451 . hal-04614622

**HAL Id: hal-04614622**

**<https://hal.science/hal-04614622v1>**

Submitted on 17 Jun 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

## POSITION STATEMENT

# Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm

Nanja van Geel<sup>1</sup>  | Reinhart Speeckaert<sup>1</sup> | Alain Taïeb<sup>2</sup>  | Khaled Ezzedine<sup>3</sup>  | Henry W. Lim<sup>4</sup> | Amit G. Pandya<sup>5</sup>  | Thierry Passeron<sup>6</sup>  | Albert Wolkerstorfer<sup>1,7</sup> | Marwa Abdallah<sup>8</sup>  | Augustin Alomar<sup>9</sup> | Jung Min Bae<sup>10</sup>  | Marcel Bekken<sup>11</sup> | Laila Benzekri<sup>12</sup>  | Markus Böhm<sup>13</sup>  | Viktoria Eleftheriadou<sup>14</sup> | Samia Esmat<sup>15</sup> | Deepti Ghia<sup>16</sup> | Boon Kee Goh<sup>17</sup> | Pearl Grimes<sup>18</sup> | Somesh Gupta<sup>19</sup>  | Iltefat H. Hamzavi<sup>4</sup> | John E. Harris<sup>20</sup> | Sang Ho Oh<sup>21</sup>  | Richard Huggins<sup>4</sup> | Ichiro Katayama<sup>22</sup> | Eric Lan<sup>23</sup>  | Ai-Young Lee<sup>24</sup> | Giovanni Leone<sup>25</sup> | Caroline Le Poole<sup>26</sup> | Harvey Lui<sup>27</sup> | Nicolle Maquignon<sup>28</sup> | Jean Marie Meurant<sup>29</sup> | Paul Monteiro<sup>30</sup> | Naoki Oiso<sup>31</sup>  | Davinder Parsad<sup>32</sup>  | Georg Pliszewski<sup>33</sup> | Noufal Raboobe<sup>34</sup> | Michelle Rodrigues<sup>35,36</sup>  | David Rosmarin<sup>37</sup> | Tamio Suzuki<sup>38</sup> | Atsushi Tanemura<sup>39</sup>  | Steven Thng<sup>40</sup> | Flora Xiang<sup>41</sup>  | Youwen Zhou<sup>27</sup> | Mauro Picardo<sup>42</sup> | Julien Seneschal<sup>43</sup> 

### Correspondence

Nanja van Geel, Department of Dermatology, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium.  
Email: [nanja.vangeel@ugent.be](mailto:nanja.vangeel@ugent.be)

### Abstract

**Background:** The treatment of vitiligo can be challenging and depends on several factors such as the subtype, disease activity, vitiligo extent, and treatment goals. Vitiligo usually requires a long-term approach. To improve the management of vitiligo worldwide, a clear and up-to-date guide based on international consensus with uniform stepwise recommendations is needed.

**Objectives:** To reach an international consensus on the nomenclature and to develop a management algorithm for the diagnosis, assessment, and treatment of vitiligo.

**Methods:** In this consensus statement, a consortium of 42 international vitiligo experts and four patient representatives participated in online and live meetings to develop a consensus management strategy for vitiligo. At least two vitiligo experts summarized the evidence of topics included in the algorithms. A survey was utilized to resolve remaining issues among a core group of eight experts. Subsequently, the unanimous recommendations were finalized and validated based on further input from the entire group during two live meetings.

**Results:** The algorithms highlight the importance of shared decision-making. Dermatologists are encouraged to provide patients with detailed explanations of the prognosis and expected therapeutic outcomes based on clinical examination.

Nanja van Geel and Reinhart Speeckaert contributed equally to this article

**Linked article:** Johannes Ring. *J Eur Acad Dermatol Venereol* 2023; 37:2157–2158. <https://doi.org/10.1111/jdv.19490>.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2023 The Authors. *Journal of the European Academy of Dermatology and Venereology* published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

The treatment goal should be discussed and clearly emphasized to patients given the different approaches for disease stabilization and repigmentation. The evaluation of disease activity remains a cornerstone in the tailor-made approach to vitiligo patients.

**Conclusions:** These new treatment algorithms are intended to guide clinical decision-making in clinical practice. Promising novel therapies for vitiligo are on the horizon, further highlighting the need for reliable outcome measurement instruments and greater emphasis on shared decision-making.

## INTRODUCTION

Vitiligo is an acquired depigmenting disorder affecting 0.5%–2% of the global population, without sex differences. It affects all age groups.<sup>1</sup> Vitiligo carries a significant disease burden, as evidenced by impairment in quality of life (QOL) and willingness to pay for treatment.<sup>2,3</sup> Both the diagnosis and treatment of vitiligo can be challenging. European (EDF/VETF/EADV/UEMS) and Japanese guidelines have been published in 2013.<sup>4,5</sup> The British and German guidelines are more recent.<sup>6,7</sup> However, an up-to-date international worldwide consensus was missing. In order to construct recommendations around the management of vitiligo, a broad initiative was conducted across the five continents, including members of the Vitiligo Task Force (VTF), East Asian Vitiligo Association (EAVA), Global Vitiligo Foundation (GVF), Vitiligo International Patient Organisations Committee (VIPOC), and other international participants. This paper summarizes evidence-based and expert-based recommendations (S1 level) and is intended for use in clinical practice (primary and secondary care). It consists of two parts. Part 1 will focus on the newly designed management algorithms for vitiligo, while part 2 (a second publication) will provide a more in-depth look at individual treatments.

## MATERIALS AND METHODS

In order to reach a broad international consensus, a consortium of 42 international experts and four patient representatives participated in this consensus effort. A list of topics was presented, optimized and approved during the expert group meetings (Vitiligo Task Force meetings). To summarize the up-to-date evidence on vitiligo, each topic was assigned to a writing group (ranging from 3 to 8 members) represented by at least two vitiligo experts who searched the literature and provided the essential data (narrative review) on which recommendations could be made for this consensus statement. The results and remaining issues were discussed during three online VTF meetings (30 September, 28 October and 9 December 2021). To get preliminary approval on the remaining issues, a digital survey was sent out to a core review group of eight vitiligo experts. Additionally, two meetings were carried out with this core review group to reach a final consensus based on the answers to the survey. Each statement received unanimous agreement, unless specified otherwise. These results were further discussed in detail with patient


representatives and vitiligo experts at the Vitiligo International Patient Organisations Committee (VIPOC) meeting (Amsterdam, April 2022) and the Vitiligo Task Force meeting (Milan, September 2022) until full agreement was reached. In total, 18 patient representatives (15 live and 3 online) participated in this VIPOC meeting. A management algorithm was constructed as a guide for the assessment, decision-making and treatment of vitiligo (Figures 1 and 2). Several versions were discussed during the online meetings, and the input of participants was incorporated into the final management model. This algorithm was first approved by the core review group, followed by a broader presentation to all vitiligo experts and discussion with vitiligo patient representatives during the VIPOC meeting and additional final conversations (email/video call). The final version of the manuscript was reviewed during the VTF meeting in Milan 9 September 2022.

## RESULTS

Management and treatment algorithms were constructed for vitiligo (non-segmental) and the segmental variant (Figures 1 and 2). In recent years, research has confirmed the value of disease activity assessment and disease extent evaluation, shared decision-making, early therapeutic intervention, maintenance therapy and combining multiple treatments. This information has been incorporated into a new management model for the treatment of vitiligo patients in daily practice. The VTF considers the information below essential for the correct implementation of the algorithms.


## DIAGNOSIS

Vitiligo is characterized by the progressive loss of melanocytes, leaving white patches on the skin. It is usually diagnosed by clinical examination alone supported by Wood's lamp examination. The differential diagnoses of vitiligo include pityriasis alba, hypopigmented mycosis fungoides, tinea versicolor, idiopathic guttate hypomelanosis, and other hypo- or depigmented disorders.<sup>8</sup> Additionally, the diagnosis of vitiligo could be wrongly made in patients with fair skin who developed due to the intervening normal skin within the melasma macules giving a vitiligo-like appearance. In cases of uncertain diagnosis, a skin biopsy, mycologic examination and appropriate blood tests may be needed to exclude a fungal infection, cutaneous lymphoma and other disorders. Routine screening of anti-thyroid antibodies and thyroid function is recommended.<sup>9</sup>



1 Other aspects for shared decision: e.g. skin type, disease duration, presence comorbidities, extent on visible/sensitive areas, geographical region.  
 2 Explain relation between body location and expected results ('best' to 'worse': face>other body areas> hands/feet); Explain the treatment expectations and limitations.  
 3 Active = new lesions or increase of existing lesions; Stable= no new lesions or no increase of existing lesions.  
 4 Clear presence of confetti-like depigmentations, hypochromic borders/areas or Koebner's phenomenon (for assessment consider e.g. Br J Dermatol. 2020;183(5):883-890; www.vitiligo-calculator.com)  
 5 NB-UVB and combination therapy preferred (e.g. phototherapy + topical corticosteroids).  
 6 Oral steroid mini pulse (most investigated) and alternatives reported: methotrexate, cyclosporine, azathioprine, minocycline and Janus Kinase (JAK) inhibitors (currently investigated).

**FIGURE 1** Recommendations for the management of vitiligo (non-segmental).



**FIGURE 2** Recommendations for the management of segmental vitiligo.

**TABLE 1** Recommended diagnostic procedures in vitiligo (modified from Taieb et al.<sup>4</sup>).

If diagnosis is uncertain	If diagnosis is certain
<ul style="list-style-type: none"> <li>• Wood's lamp examination to differentiate between hypochromic and depigmented skin</li> <li>• Punch biopsy from lesional skin (and optional non- or perilesional or depending on differential diagnoses)</li> <li>• Other tests if needed (mycology, molecular testing to detect lymphoma cells, etc.)</li> </ul>	<ul style="list-style-type: none"> <li>• Anti-thyroid peroxidase (TPO) antibodies, thyroid stimulating hormone (TSH) as a routine screening. If needed<sup>a</sup> other tests to assess thyroid function or diagnosis</li> <li>• Additional autoantibodies only if patient's history, family history and/or laboratory parameters point to a strong risk of additional autoimmune disease</li> <li>• Endocrinologist/immunologist advice if multiple autoimmune diseases detected</li> </ul>

<sup>a</sup>e.g. in case of abnormal routine thyroid screening and clinically/history based.

If the patient's history or routine laboratory parameters suggest additional autoimmune disorders, further investigation and management are strongly suggested (Table 1).

## NOMENCLATURE/TERMINOLOGY

The term 'vitiligo (non-segmental)' referring to all forms of vitiligo except segmental vitiligo was preferred based on the current consensus statement and will overrule the previous agreed umbrella term 'vitiligo'.<sup>10</sup> The addition of 'non-segmental' was considered to be less confusing for communication (in papers, trials and daily practice). Segmental vitiligo (SV) refers to a clinically unilateral segmental distribution of depigmented lesions. The coexistence of SV plus vitiligo (non-segmental) is called mixed vitiligo. Focal vitiligo, a term that applies to localized macules characterized by loss of melanocytes, was assigned to the category undetermined/unclassified until more definitive classification can be made on clinical grounds (generally after 1–2 years of follow-up). Cases with long-lasting focal lesions or of pure mucosal vitiligo, if not classified as SV, may remain 'unclassified'. The modified nomenclature/classification is summarized in Table 2. An international consensus was also reached to define different dimensions of vitiligo activity (e.g. rapidly spreading/progressive) based on patient input and subsequent validation during the conclusive meeting (Table 3).

## INITIAL PATIENT ASSESSMENT

Experts recommend a comprehensive initial visit (e.g. 30–45 min) for a good assessment and enough time with the patient to discuss pathogenesis, prognosis, management, treatment rationale and practical aspects. Initial vitiligo-oriented assessment (in addition to a general medical history including current medication) includes documentation of the different aspects of the disease (e.g. by history and clinical examination) as well as clinical photography (digital imaging).<sup>11</sup> Table 4 proposes a checklist of the most important assessment items. Parallel to the central therapeutic paradigm to limit pigment cell damage, it is crucial to tailor

**TABLE 2** Modified classification (2023) and consensus nomenclature (modified from Ezzedine et al.<sup>10</sup>).

Vitiligo (non-segmental)	Segmental vitiligo: Uni-, bi- or plurisegmental	Undetermined/unclassified vitiligo
<ul style="list-style-type: none"> <li>• Acrofacial</li> <li>• Mucosal (more than one mucosal site)</li> <li>• Generalized</li> <li>• Universal<sup>a</sup></li> <li>• Mixed (associated with segmental vitiligo)</li> <li>• Rare variants</li> </ul>	<ul style="list-style-type: none"> <li>• uni-, bi-<sup>a</sup>, or pluri-<sup>a</sup>segmental</li> </ul>	<ul style="list-style-type: none"> <li>• Focal</li> <li>• Mucosal (one site in isolation)<sup>a</sup></li> </ul>

<sup>a</sup>Rare forms of vitiligo.

**TABLE 3** Consensus definitions related to vitiligo (both segmental and non-segmental) 'activity'.

Term	Definition
• Rapidly spreading/progressive	Rapidly progressive/spreading vitiligo is defined as vitiligo in which a large number of new spots and/or a significant enlargement of existing spots have appeared over the past 3 months
• Stable/active	<ul style="list-style-type: none"> <li>• "A 12-month period of photographically assessed stability is deemed appropriate to consider a lesion 'stable' for the purpose of surgical treatment."<sup>a</sup></li> <li>• Most appropriate cut-off point to define stable vitiligo is 12 months according to the majority of experts.<sup>b</sup></li> </ul>

<sup>a</sup>Based on previous consensus, specifically in the context of surgical interventions.<sup>10</sup>

<sup>b</sup>Data from VGICC-Rome November 30–December 3, 2016 meeting (unpublished): survey around the definition of stable/active with international experts.<sup>53</sup> Note: N = 28—What cut-off point do you believe is most appropriate to define stable vitiligo? 12 months: 57%; 6 months: 21%; 24 months: 11%; 3 and 18 months: 11%.

interventions based on overall profile, with thorough assessment of several dimensions such as disease activity, location of lesions, disease extent, stage of available resources for repigmentation (e.g. pigmented hairs/no leukotrichia), prognosis depending on the anatomical sites of involvement and impact on quality of life.

**TABLE 4** Modified assessment check list.<sup>4</sup>

<b>Patient's characteristics</b>
<ul style="list-style-type: none"> <li>• Skin phototype/ethnicity</li> <li>• History of autoimmune disease (thyroid disease and other autoimmune diseases)</li> <li>• General health, medication</li> </ul>
<b>Disease features</b>
<ul style="list-style-type: none"> <li>• Type of vitiligo (non-segmental, segmental, unclassified)</li> <li>• Disease duration/age of vitiligo onset</li> <li>• Disease extent (physician-reported: VES<sup>a</sup>, VASI; patient-reported: SAVES<sup>a</sup>) and/or global assessment (physician-reported: PGA; patient-reported: PtGA)<sup>12,14,18,20,22</sup></li> <li>• Location of lesions (e.g. including visible areas and genital involvement)</li> <li>• Presence and number of halo nevi</li> <li>• Presence of white hairs (leukotrichia)</li> <li>• Disease activity in the past 6 months according to patient and physician (progressive, stable, regressive)<sup>27</sup>; use of standardized photography recommended<sup>11</sup></li> <li>• Disease activity signs assessed by physicians [Koebner 2B phenomenon, confetti-like depigmentation, hypochromic lesions/borders; e.g. (VSAS)<sup>a,26</sup>]</li> <li>• Triggering factors</li> </ul>
<b>Burden of the disease</b>
<ul style="list-style-type: none"> <li>• Quality of life [e.g. Vitiligo Quality of Life scale (VitiQol)]<sup>30</sup></li> <li>• Disease impact [e.g. Vitiligo Impact Scale (VIPs), Vitiligo Impact Scale (VIS-22), vitiligo 0–10 impact scale]<sup>22,28,29,31</sup></li> </ul>
<b>Family history</b>
<ul style="list-style-type: none"> <li>• Vitiligo</li> <li>• Autoimmune/inflammatory diseases</li> </ul>
<b>Previous and current interventions</b>
<ul style="list-style-type: none"> <li>• For vitiligo: type, duration, response</li> <li>• For associated disorders</li> </ul>

Abbreviations: PGA, physician global assessment; PtGA, patient global assessment; SAVES, self-assessment vitiligo extent score; VASI, vitiligo area scoring index; VES, vitiligo extent score; VSAS, vitiligo signs of activity score.

<sup>a</sup>[www.vitiligo-calculator.com](http://www.vitiligo-calculator.com).

## SEVERITY SCORING METHODS

The objective assessment of vitiligo is based essentially on extent. Several instruments are available [e.g. vitiligo area scoring index (VASI), Vitiligo European Task Force assessment tool (VETFa); Vitiligo Extent Score (VES) and VE-Splus; [www.vitiligo-calculator.com](http://www.vitiligo-calculator.com)].<sup>12-15</sup> Their reliability, validity and responsiveness are reported.<sup>16,17</sup> The patient-reported version (SA-VES) can easily be used in daily clinical practice.<sup>18</sup> For target lesions, mostly in the context of clinical trials, digital image analysis can be proposed.<sup>19</sup> Stratification of extent and severity into global categories (limited/mild, moderate, extensive/severe) based on one study (patients' perspective) was as follow: Extent  $\leq 1.05\%$  BSA for limited,  $>1.05\%$ – $6.45\%$  for moderate and  $>6.45\%$  for extensive, Severity  $\leq 2.07\%$  BSA for mild,  $>2.07\%$ – $4.8\%$  for moderate and  $>4.8\%$  for severe.<sup>20-22</sup> Extent represents only one aspect of the 'severity' perception from the patients' perspective; therefore, other items need to be taken into account, for instance, location of lesions (visible areas), disease impact, skin phototype and disease activity.<sup>21</sup>

## ASSESSMENT AND SCORING OF DISEASE ACTIVITY

Several visible clinical skin manifestations in vitiligo (Figure 1) are reported in relation to disease progression such as confetti-like depigmentation, inflammatory borders, Koebner phenomenon and hypochromic areas/borders.<sup>23-25</sup> For a standardized assessment, the Vitiligo Signs of Activity Score (VSAS) can be used.<sup>26</sup> This can be combined with a clinical assessment of vitiligo evolution (progressive, stable, improving), comparing two different time points (e.g. 6 months) [e.g. Vitiligo Disease Activity Score (VDAS) and Vitiligo Disease Improvement Score (VDIS)].<sup>27</sup> Photography is an important adjunct in the assessment of vitiligo disease activity. A protocol including recommendations for standardized vitiligo photography has been developed within the VGICC/GVF imaging group.<sup>11</sup>

## ASSESSMENT OF THE DISEASE BURDEN

Low self-esteem and high levels of perceived stigma are important factors for quality of life (QOL) impairment in vitiligo patients. Quality of life measurements should be considered in all patients and intervention, guidance and support should be offered if required. The burden/impact can be assessed globally (e.g. Vitiligo global Impact scale 0 to 10 or 5-point scale), or with a more comprehensive burden scale [e.g. Vitiligo Impact Patient Scale (VIPs), Vitiligo Quality of Life scale (VitiQOL) and Vitiligo Impact Scale (VIS-22)].<sup>21,22,28-33</sup>

Management of the psychological implications of vitiligo is an important aspect of overall disease management.<sup>34</sup> Psychological support includes but is not limited to counselors, psychologists and psychiatrists, and depends on local resources, networking and the extent of the morbidity.

The treating physician should regard the announcement of the disease as important. One should try to allow for sufficient time in the visit to address the many potential questions. A second visit a few weeks following the initial diagnosis may also be beneficial as it allows for the patient and caretaker to process the condition and information from the first visit, reflect on it and formulate more questions if required. Support groups and vitiligo patient organizations (e.g. VIPOC, Global Vitiligo Foundation Support Community (GVFSC) or national organizations) can be discussed during the initial consultation if appropriate. Vitiligo patients should preferably be provided with a written or electronic information leaflet describing the disorder, the prescribed therapies and options for psychological support (self-help or psychological services).

The lives of patients with vitiligo affecting exposed body surfaces may be significantly improved by 'camouflage' or corrective makeup advice given by professional makeup

artists, and this should be discussed by the physician as a part of management strategy. In addition, information about the use of sunscreens and increased sun sensitivity of the depigmented skin should be provided.

## FRAMING PATIENT EXPECTATIONS, TREATMENT GOALS AND SHARED DECISION-MAKING

Detection and treatment of vitiligo at an early stage are considered to be essential for optimal management. The timeline to obtain expert advice and start an effective treatment is often too long. There is clinical evidence among experts that early aggressive intervention is essential to improve prognosis.<sup>35</sup> Limiting disease progression with an active immune/anti-inflammatory approach is beneficial for all types of vitiligo, including segmental vitiligo (in particular during the early developmental stages).<sup>36</sup> Based on our current understanding, early aggressive treatment is now considered appropriate in rapidly progressive vitiligo to limit irreversible damage to pigment cells.<sup>35,36</sup> Patients are frequently frustrated by the failure of previous treatments, and undertreatment is very common. It is thus essential in the evaluation of patients that the appropriateness of previous therapy is assessed, as well as patient compliance. This is particularly true, if established treatments are reported as not efficacious. Stable vitiligo needs treatment to regenerate epidermal melanocytes from the hair follicle or interfollicular precursors, while some subtypes with a limited reservoir of melanocyte precursors such as stable segmental vitiligo are often out of reach of actual immune/inflammatory targeted therapies and may need surgical interventions.<sup>37</sup>

Concerning treatment goals, the distinction between disease stabilization and repigmentation should be clearly emphasized for patients. Most current treatments are immune-modulating and display good to excellent results regarding disease stabilization. Nonetheless, in most cases additional stimulation of (precursors of) melanocytes is also beneficial (e.g. by UV exposure). The chance of repigmentation is highly dependent on the body locations involved.<sup>38</sup> This should be explained to the patient in order to make an informed decision regarding an attainable treatment goal. Different components of disease severity are important for making management decisions such as disease activity, disease extent, location in visible areas, psychological/social impact and skin phototype. The shared decision-making (SDM) concept is a new strategy recently developed in vitiligo. The goal is to make patients aware of the availability of different therapeutic choices, to discuss their preferences and clarify the therapeutic options, including disadvantages, risks and benefits. A SDM tool has been recently developed and validated for vitiligo and could be an important part of the management of the disease.<sup>39</sup>

## TREATMENT RECOMMENDATIONS

### General remarks

Management algorithms for both vitiligo (non-segmental) and segmental vitiligo were developed (Figures 1 and 2). Based on shared decision-making, the treatment goals, disease activity and extent, the therapeutic choice can be made by the clinician using the algorithms. The vitiligo expert group generally recommends treatment for the vast majority of vitiligo patients and perceives current undertreatment of vitiligo by dermatologists. Nonetheless, the shared decision-making process may in some cases result in simple reassurance with continued observation (wait-and-see approach), depending on the desires of the patient.

In the case of active vitiligo, topical treatment, phototherapy and/or in rapidly progressive vitiligo systemic treatment are suggested. In the case of stable vitiligo, maintenance treatment should be considered to prevent flares and topical treatment with or without phototherapy can be considered for repigmentation. Surgical techniques are reserved for vitiligo which is stable for at least 12 months without treatment. For all treatments, safety should be discussed with the patient. This holds true in particular for systemic treatments, UV exposure therapies and combination therapies. We recommend reevaluation of the treatment every 3 to 6 months to check for improvement based on serial photography. Because a long course is usually required, one should consider the risk-benefit ratio for each treatment.

### Therapeutic options

For topical treatment, potent to very potent corticosteroids and the topical calcineurin inhibitors tacrolimus and pimecrolimus can be recommended. The topical JAK inhibitor ruxolitinib cream 1.5% is now the first FDA and EMA approved treatment for vitiligo (non-segmental) and is also an option.

For phototherapy, NB-UVB (in office or home phototherapy) can be recommended in vitiligo patients with insufficient response to topical treatment and/or in extensive or rapidly progressive disease. Phototherapy can be given with excimer devices (laser or lamp) and are suited for more localized forms of vitiligo. Systemic treatment that is most commonly used consists of oral steroid mini pulse therapy, which has been used mainly for more extensive or rapidly progressive disease. Alternatives reported are methotrexate, cyclosporine, azathioprine and minocycline, but data remain limited to support their use. The topical JAK inhibitor, ruxolitinib, has recently been approved, and the efficacy and safety of other topical and systemic JAK inhibitors are currently being evaluated as well. Surgery is an option for patients with SV or other



treatment resistant localized forms of vitiligo after disease stability for at least 12 months. Detailed recommendations for each therapeutic option and other interventions are provided in part 2.

## Combination treatment

Combination treatments are in general considered more effective than monotherapy. Safety needs to be discussed with the patient before starting the combination treatments (e.g. theoretical increased risk of skin cancer and other malignancies). The following options are reported:

- Phototherapy with topicals: Generally, the combination of phototherapy with topicals (both calcineurin inhibitors, topical steroids and topical ruxolitinib) achieves better efficacy.<sup>40-44</sup> As to which combination is better, the number of published studies is currently too limited to make a fair judgment.
- Combination with systemic antioxidants: There is some evidence to recommend the combination of phototherapy with oral antioxidants like polygodium leucotomos and gliadin-protected SuperOxide Dismutase (SOD) for achieving better repigmentation.<sup>45-47</sup>
- Combination of systemic immunosuppressives with phototherapy: Most systemic immunosuppressive therapies can induce repigmentation when given in combination with phototherapy.<sup>48</sup> However, administering guidelines based on RCTs including an evaluation of efficiency and safety aspects are lacking. Therefore, careful consideration of the risks and benefits should be taken into account prior to starting therapy.

## Maintenance treatment

After successful repigmentation, the rate of relapse in vitiligo lesions is about 44% in the first year after discontinuation of the treatment.<sup>49</sup> Bi-weekly application of 0.1% tacrolimus ointment decreases relapse after repigmentation compared to placebo (9.7% compared to 40% after 6 months).<sup>50</sup> The optimal duration of such a maintenance therapy is still not defined, although a minimum period of 6 months after repigmentation makes sense.

Topical steroids may have a similar effect, although published data are lacking. Based on the experience of the experts, twice weekly application of potent topical steroids can be used in place of topical tacrolimus to prevent relapses, especially in non-sensitive areas. Data regarding the use of topical ruxolitinib cream as a maintenance therapy are lacking. For widespread vitiligo, a topical maintenance scheme could be considered for a selection of relevant areas. Although of great interest, significant evidence to support the use Narrowband-UVB (NB-UVB) or systemic treatments as maintenance therapies is currently lacking.<sup>51-53</sup>

## Additional considerations for using the algorithm specifically for children or during pregnancy

### Children

Age and developmental stage will affect how vitiligo affects children. The child's level of concern about the condition or future impact should be considered when making treatment decisions, including whether or not to actively treat. In general, there are no clearly defined treatment guidelines for children and adolescents, due to a lack of strong evidence related to efficacy and safety aspects within this particular group.

Some evidence was provided that early treatment for paediatric patients yields the best results.<sup>54</sup> Data supporting the safety of phototherapy in children are however limited, and caution is advised. Although cellular grafts and punch minigrafting in children have been described, there is no consensus regarding the minimum age for surgery.<sup>55</sup> As the techniques are time-consuming and require cooperation from the patient, surgery has in general been proposed at a later age.<sup>55,56</sup>

### Pregnancy

Data concerning the prognosis of vitiligo during or shortly after pregnancy are limited, but worsening of existing vitiligo may occur, suggesting more careful follow-up.<sup>57</sup> A recent large Korean study indicates that vitiligo is significantly associated with an increased risk of spontaneous abortion.<sup>58</sup> The treatments that have been reported to be safe for use during pregnancy as well as during lactation are topical steroids in limited areas and NB-UVB, although it is important to recommend folate supplementation and monitor for the development of melasma. Depending on the activity of vitiligo, limiting the cumulative amount of very potent topical steroids to less than 300g during the entire pregnancy may be advisable given the possible association with low birth weight.<sup>59</sup>

## DISCUSSION/CONCLUSION

Based on international worldwide collaboration, we developed a new treatment algorithm for the management of vitiligo. These recommendations emphasize the importance of recognizing the burden of vitiligo on patients. A correct assessment of disease activity, vitiligo extent and involved locations is crucial to frame patient expectations concerning the natural evolution and treatment results. We believe that these recommendations facilitate a shared-decision process which is of particular importance in vitiligo given the high variability in treatment results and patients' expectations.

## AFFILIATIONS

- <sup>1</sup>Department of Dermatology, Ghent University Hospital, Ghent, Belgium
- <sup>2</sup>Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-André, BRIC, UMR 1312, Inserm, University Bordeaux, Bordeaux, France
- <sup>3</sup>Department of Dermatology, University Hospital Henri Mondor, EpiDermE EA 7379, Université Paris-Est Créteil Val de Marne, Créteil, France
- <sup>4</sup>Department of Dermatology, Henry Ford Health, Detroit, Michigan, USA
- <sup>5</sup>Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA
- <sup>6</sup>Department of Dermatology, University Hospital of Nice, Nice, France
- <sup>7</sup>Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, Amsterdam Institute for Infection and Immunity, University of Amsterdam, Amsterdam, The Netherlands
- <sup>8</sup>Dermatology, Andrology, and Venereology Department, Ain Shams University, Cairo, Egypt
- <sup>9</sup>Department of Dermatology, Clinica Dermatologica Moragas, Barcelona, Spain
- <sup>10</sup>Department of Dermatology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
- <sup>11</sup>Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, Amsterdam Institute for Infection and Immunity, VU University, Amsterdam, The Netherlands
- <sup>12</sup>Department of Dermatology, Ibn Sina University Hospital, Mohammed V University, Rabat, Morocco
- <sup>13</sup>Department of Dermatology, University Hospital Münster, Münster, Germany
- <sup>14</sup>New Cross Hospital, The Royal Wolverhampton NHS Trust, Wolverhampton, UK
- <sup>15</sup>Department of Dermatology, Faculty of Medicine, Cairo University, Cairo, Egypt
- <sup>16</sup>Department of Dermatology, Jaslok Hospital and Research Hospital and South Mumbai Dermatology Clinic, Mumbai, India
- <sup>17</sup>Skin Physicians Pte Ltd, Mount Elizabeth Medical Centre, Singapore City, Singapore
- <sup>18</sup>Vitiligo & Pigmentation Institute of Southern California, Los Angeles, California, USA
- <sup>19</sup>Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India
- <sup>20</sup>Department of Dermatology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA
- <sup>21</sup>Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, South Korea
- <sup>22</sup>Pigmentation Research and Therapeutics, Osaka Metropolitan University, Osaka, Japan
- <sup>23</sup>Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
- <sup>24</sup>Department of Dermatology, College of Medicine, Dongguk University Ilsan Hospital, Goyang, Korea
- <sup>25</sup>Photodermatology and Vitiligo Treatment Unit, Israelite Hospital, Roma, Italy
- <sup>26</sup>Departments of Dermatology, Microbiology and Immunology, Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago, Illinois, USA
- <sup>27</sup>Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada
- <sup>28</sup>Association Française du Vitiligo, Paris, France
- <sup>29</sup>Vitiligo International Patient Organisations Committee, Paris, France
- <sup>30</sup>Vitiligo.nl, Den Haag, The Netherlands
- <sup>31</sup>Department of Dermatology, Kindai University Nara Hospital, Ikoma, Japan
- <sup>32</sup>Department of Dermatology, Venereology & Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
- <sup>33</sup>Deutscher Vitiligo-Bund e.V., Adelsdorf, Germany
- <sup>34</sup>Department of Dermatology, Westville Hospital, Durban, South Africa
- <sup>35</sup>Chroma Dermatology, Pigment and Skin of Colour Centre, Parkville, Victoria, Australia
- <sup>36</sup>Department of Dermatology, The Royal Children's Hospital, Parkville, Victoria, Australia
- <sup>37</sup>Department of Dermatology, Tufts University School of Medicine, Boston, Massachusetts, USA
- <sup>38</sup>Department of Dermatology, Yamagata University Faculty of Medicine, Yamagata, Japan
- <sup>39</sup>Department of Dermatology Integrated Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
- <sup>40</sup>Skin Research Institute of Singapore, ASTAR, Singapore City, Singapore
- <sup>41</sup>Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China
- <sup>42</sup>Unicamillus International University, Rome, Italy
- <sup>43</sup>Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin disorders, Hospital Saint-André, University of Bordeaux, CNRS UMR 5164, ImmunoConcept, Bordeaux, France

## ACKNOWLEDGEMENTS

We are grateful to all the participating patient representatives and vitiligo experts who attended the VTF meetings, VIPOC meetings, and final VTF conclusive consensus meeting in Milan (EADV 2022). We express our deep gratitude to all patient representatives who played a significant role in the development of this work through their dedicated involvement in the process (JMM, NM, PM, GP).

## FUNDING INFORMATION

No funding.

## CONFLICT OF INTEREST STATEMENT

**Nanja van Geel** MD, PhD received grants, is consultant and/or investigator for AbbVie, Incyte, Merck/MSD, Pfizer and Sun Pharma; and is chair of the Vitiligo Task Force for the European Academy of Dermatology and Venereology (EADV). She was involved in the development of several measurement instruments for vitiligo. **Khaled Ezzedine** MD, PhD has served as a consultant for AbbVie, Incyte Corporation, Pfizer, Pierre Fabre Pharmaceuticals, Merck/MSD and Almirall. **Amit G. Pandya** MD has served as an investigator for Incyte. He is a consultant for AbbVie, Avita Medical, Immune Tolerance Network, Incyte, Pfizer, Thalocan, Trifecta, TWi, Viela Bio, Vyne, and Villarix and holds stock options for Tara Medical and Zerigo Health. **Thierry Passeron** MD, PhD received consultancy fees from Abbvie, Incyte, Pfizer, Vyne therapeutics and Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from from Abbvie, Incyte, Pfizer, Vyne therapeutics. **Albert Wolkerstorfer** MD, PhD, is consultant for Incyte, Novartis, AvitaMedical, Candela and Lumenis. **Jung Min Bae** MD, PhD has served as a consultant for Pfizer, AbbVie, LaserOptek, Ilooda and Cotech Korea. **Viktoria Eleftheriadou** MD, PhD VE is a consultant for Incyte, Abbvie, Pfizer and Almirall. **Samia Esmat** MD is consultant for Pfizer. **Pearl Grimes** MD conducts clinical trials, for which the Vitiligo & Pigmentation Institute of Southern California receives financial support for purposes of conducting these trials, from Procter & Gamble, Clinuvel, L'Oreal, Johnson & Johnson, LaserOptek, Mother Science, Incyte, Pfizer, AbbVie/Allergan and SkinBetterScience. Dr. Grimes receives no direct compensation for this work. **Somesh Gupta** MD is conducting a clinical trial sponsored by Pfizer on Abrocitinib and Ritlecitinib. **Iltefat H. Hamzavi** MD is Consultant to Abbvie, Pfizer, Incyte, UCB, Boehringer Ingelheim, Sonoma, Union therapeutics, Novartis, Jansen, Avita, Galderma and is Investigator for Lenicura, Pfizer, Incyte, Avita, L'oreal/La Roche Posay. He is also Board member and Past-president of the HS foundation and Global Vitiligo foundation. **John E. Harris** MD, PhD, 3rd Rock Venture – Consultant (Fees); AbbVie, Inc – Consultant (Fees); Aclaris Therapeutics, Inc – Consultant (Fees), Investigator (Grants/Research Funding); Admirx—Consultant (Fees); Aldena—Consultant (Fees), Founder (Stock); Almiral—Consultant (Fees); AnaptysBio—Consultant (Fees); Avita—Consultant (Fees); BiologicsMD—Consultant (Fees); Boston Pharma—Consultant (Fees); BridgeBio—Consultant

(Fees); Celgene—Investigator (Grants/Research Funding); Cogen Therapeutics—Consultant (Fees); Dermavant—Consultant (Fees), Investigator (Grants/Research Funding); Dermira—Consultant (Fees); EMD Serono—Consultant (Fees), Investigator (Grants/Research Funding); Frazier Management—Consultant (Fees); Genzyme/Sanofi—Consultant (Fees), Investigator (Grants/Research Funding); Granular Therapeutics, Inc—Consultant (Fees); Incyte—Consulting (Fees), Investigator (Grants/Research Funding), Equity; Janssen—Consultant (Fees); LEO Pharma—Consultant (Fees), Investigator (Grants/Research Funding); Matchpoint Therapeutics—Consultant (Fees); Merck—Consultant (Fees); NIRA Biosciences—Consultant (Fees), Founder (Stock); Pandion—Consultant (Fees); Pfizer—Consultant (Fees), Investigator (Grants/Research Funding); Platelet Biogenesis—Consultant (Fees); Rheos Medicines—Consultant (Fees), Investigator (Grants/Research Funding), Equity (Stock); Sonoma Biotherapeutics—Consultant (Fees); Steifel/GSK—Investigator (Grants/Research Funding); Sun Pharmaceuticals—Consultant (Fees), Investigator (Grants/Research Funding); Temprian Therapeutics—Consultant (Fees); TeVido BioDevices—Consultant (Fees), Investigator (Grants/Research Funding), Equity (Stock); Twi Biotech—Consultant (Fees); Villarix Therapeutics—Consulting (Fees), Investigator (Grants/Research Funding), Founder (Stock); Vimela Therapeutics—Consultant (Fees), Founder (Stock); Villarix Therapeutics was recently acquired by Incyte. **Sang Ho Oh** MD, PhD has served as a consultant for Merck/MSD. **Richard H. Huggins** MD has served as an investigator for Arcutis, Avita, Clinuvel, Incyte, Pfizer and The Immune Tolerance Network; and is Treasurer of The Global Vitiligo Foundation. **Eric Lan** MD, PhD, has served for Pfizer, Dermira (Eli Lilly), Abbvie, Teva Pharmaceutical, Cerner Enviza clinical trials. None of the trials focus on vitiligo. **Caroline Le Poole** PhD is the CSO of Temprian Therapeutics, promoting the clinical translation of HSP70i<sub>Q435A</sub> for the treatment of vitiligo. **Harvey Lui** MD is a consultant (fees to professional medical corporation) for Incyte and has been a clinical investigator (fees to institution) for Pfizer in vitiligo. **Jung Min Bae** MD, PhD has served as a consultant for Pfizer, AbbVie, LaserOptek, Il-ooda and Cutech Korea. **Noufal Raboobe** MD has received honoraria from AbbVie, Pfizer, Novartis, Lilly, Janssen and Sanofi, is the President of the Dermatology Society of South Africa and President of the Vitiligo Society of South Africa. **David Rosmarin** MD received honoraria as a consultant for AbbVie, Abcuro, AltruBio, Arena, Boehringer-Ingelheim, Bristol Meyers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Incyte, Janssen, Kyowa Kirin, Lilly, Novartis, Pfizer, Regeneron, Recludix, Revolo Biotherapeutics, Sanofi, Sun Pharmaceuticals, UCB, VielaBio; has received research support from AbbVie, Amgen, Bristol Meyers Squibb, Celgene, Dermira, Galderma, Incyte, Janssen, Lilly, Merck, Novartis, Pfizer, and Regeneron Pharmaceuticals Inc; and has served as a paid speaker for AbbVie, Amgen, Bristol Meyers Squibb, Celgene, Dermavant, Incyte, Janssen, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals Inc. and

Sanofi. **Tamio Suzuki** MD, PhD has served as a consultant for AbbVie, Pfizer, J-TEC and Pola; and is the secretary general of the Japanese Society of Vitiligo. **Mauro Picardo** MD, received grants or honoraria from PPM, Naos, Incyte and Pfizer and has a patent on Pioglidazone in Vitiligo. **Julien Seneschal** MD, PhD received grants and/or honoraria from AbbVie, Bristol Myers Squibb, Calypso Biotech, Eli Lilly, Incyte, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Sanofi, Sun Pharmaceuticals and Viela Bio; and has a patent on MMP9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder and three-dimensional model of depigmenting disorder. All other co-author have no disclosure to declare.

## DISCLAIMER

This recommendation was proposed based on expert opinions, feedback from patient representatives and published evidence. Future updates of these recommendations are inevitable as new treatments and potential adverse responses may override current management recommendations. The Vitiligo Task Force does not represent or warrant a legislative or all-encompassing consensus based on the contents of this documentation/statement. Medical professionals may treat vitiligo following procedures and treatment plans that substantially differ from those mentioned or described in this recommendation. The Vitiligo Task Force expressly disclaims any responsibility or liability for any damages, loss, injury or liability whatsoever experienced as a result of reliance on the information contained in this publication. The contents of this manuscript can in no way be regarded as advice in legal matters (including use for claims). Inquiring about allergies and intolerance reactions, as well as detecting probable contraindications, are steps that should be considered part of a physician's general responsibilities when prescribing medications. All patients should be informed of the specific risks associated with each recommended treatment.











## DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analysed in this study.

## ETHICS STATEMENT

Not applicable.

## ORCID

*Nanja van Geel*  <https://orcid.org/0000-0002-3249-8195>  
*Alain Taïeb*  <https://orcid.org/0000-0002-0928-8608>  
*Khaled Ezzedine*  <https://orcid.org/0000-0002-5468-4589>  
*Amit G. Pandya*  <https://orcid.org/0000-0002-3916-2651>  
*Thierry Passeron*  <https://orcid.org/0000-0002-0797-6570>  
*Marwa Abdallah*  <https://orcid.org/0000-0002-7791-9141>  
*Jung Min Bae*  <https://orcid.org/0000-0001-5975-8519>  
*Laila Benzekri*  <https://orcid.org/0000-0003-1885-6563>  
*Markus Böhm*  <https://orcid.org/0000-0001-7338-7734>  
*Somesh Gupta*  <https://orcid.org/0000-0003-3015-8602>  
*Sang Ho Oh*  <https://orcid.org/0000-0002-4477-1400>  
*Eric Lan*  <https://orcid.org/0000-0003-4654-118X>

Naoki Oiso  <https://orcid.org/0000-0001-5593-6496>  
 Davinder Parsad  <https://orcid.org/0000-0001-9820-7875>  
 Michelle Rodrigues  <https://orcid.org/0000-0002-9747-1882>  
 Atsushi Tanemura  <https://orcid.org/0000-0002-5239-8474>  
 Flora Xiang  <https://orcid.org/0000-0002-2712-3962>  
 Julien Seneschal  <https://orcid.org/0000-0003-1139-0908>

## REFERENCES

- Picardo M, Dell'Anna ML, Ezzedine K, Hamzavi I, Harris JE, Parsad D, et al. Vitiligo. *Nat Rev Dis Primers*. 2015;1:15011. <https://doi.org/10.1038/nrdp.2015.11>
- Beikert FC, Langenbruch AK, Radtke MA, Kornek T, Purwins S, Augustin M. Willingness to pay and quality of life in patients with atopic dermatitis. *Arch Dermatol Res*. 2014;306(3):279–86. <https://doi.org/10.1007/s00403-013-1402-1>
- Ezzedine K, Eleftheriadou V, Jones H, Bibeau K, Kuo FI, Sturm D, et al. Psychosocial effects of vitiligo: a systematic literature review. *Am J Clin Dermatol*. 2021;22(6):757–74. <https://doi.org/10.1007/s40257-021-00631-6>
- Taieb A, Alomar A, Böhm M, Dell'anna M, de Pase A, Eleftheriadou V, et al. Guidelines for the management of vitiligo: the European dermatology forum consensus. *Br J Dermatol*. 2013;168(1):5–19. <https://doi.org/10.1111/j.1365-2133.2012.11197.x>
- Oiso N, Suzuki T, Wataya-Kaneda M, Tanemura A, Tanioka M, Fujimoto T, et al. Guidelines for the diagnosis and treatment of vitiligo in Japan. *J Dermatol*. 2013;40(5):344–54. <https://doi.org/10.1111/1346-8138.12099>
- Eleftheriadou V, Atkar R, Batchelor J, McDonald B, Novakovic L, Patel JV, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. *Br J Dermatol*. 2022;186(1):18–29. <https://doi.org/10.1111/bjd.20596>
- Böhm M, Schunther JA, Fritz K, Salavastru C, Dargatz S, Augustin M, et al. S1 guideline: diagnosis and therapy of vitiligo. *J Dtsch Dermatol Ges*. 2022;20(3):365–78. <https://doi.org/10.1111/ddg.14713>
- Speeckaert R, van Geel N. Vitiligo: an update on pathophysiology and treatment options. *Am J Clin Dermatol*. 2017;18(6):733–44. <https://doi.org/10.1007/s40257-017-0298-5>
- Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. *Lancet*. 2015;386(9988):74–84. [https://doi.org/10.1016/S0140-6736\(14\)60763-7](https://doi.org/10.1016/S0140-6736(14)60763-7)
- Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CCE, et al. Revised classification/nomenclature of vitiligo and related issues: the vitiligo global issues consensus conference. *Pigment Cell Melanoma Res*. 2012;25(3):E1–E13. <https://doi.org/10.1111/j.1755-148X.2012.00997.x>
- van Geel N, Hamzavi I, Kohli I, Wolkerstorfer A, Lim HW, Bae JM, et al. Standardizing serial photography for assessing and monitoring vitiligo: a core set of international recommendations for essential clinical and technical specifications. *J Am Acad Dermatol*. 2020;83(6):1639–46. <https://doi.org/10.1016/j.jaad.2019.10.055>
- Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the vitiligo area scoring index. *Arch Dermatol*. 2004;140(6):677–83. <https://doi.org/10.1001/archderm.140.6.677>
- Taieb A, Picardo M, VETF Members. The definition and assessment of vitiligo: a consensus report of the vitiligo European task force. *Pigment Cell Res*. 2007;20(1):27–35. <https://doi.org/10.1111/j.1600-0749.2006.00355.x>
- van Geel N, Lommerts J, Bekkenk M, Wolkerstorfer A, Prinsen CAC, Eleftheriadou V, et al. Development and validation of the vitiligo extent score (VES): an international collaborative initiative. *J Invest Dermatol*. 2016;136(5):978–84. <https://doi.org/10.1016/j.jid.2015.12.040>
- van Geel N, Wolkerstorfer A, Lommerts JE, Ezzedine K, Eleftheriadou V, Hamzavi I, et al. Validation study of the vitiligo extent score-plus. *J Am Acad Dermatol*. 2018;78(5):1013–5. <https://doi.org/10.1016/j.jaad.2017.11.032>
- van Geel N, Bekkenk M, Lommerts JE, Ezzedine K, Harris J, Hamzavi I, et al. The vitiligo extent score (VES) and the VESplus are responsive instruments to assess global and regional treatment response in patients with vitiligo. *J Am Acad Dermatol*. 2018;79(2):369–71. <https://doi.org/10.1016/j.jaad.2017.12.070>
- Komen L, da Graça V, Wolkerstorfer A, de Rie MA, Terwee CB, van der Veen JPW. Vitiligo area scoring index and vitiligo European task force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo. *Br J Dermatol*. 2015;172(2):437–43. <https://doi.org/10.1111/bjd.13432>
- van Geel N, Lommerts JE, Bekkenk MW, Prinsen CA, Eleftheriadou V, Taieb A, et al. Development and validation of a patient-reported outcome measure in vitiligo: the self assessment vitiligo extent score (SA-VES). *J Am Acad Dermatol*. 2017;76(3):464–71. <https://doi.org/10.1016/j.jaad.2016.09.034>
- van Geel N, Vandendriessche D, Vandersichel E, De Schepper S, Grine L, Mertens L, et al. Reference method for digital surface measurement of target lesions in vitiligo: a comparative analysis. *Br J Dermatol*. 2019;180(5):1198–205. <https://doi.org/10.1111/bjd.17190>
- van Geel N, Wolkerstorfer A, Ezzedine K, Pandya AG, Bekkenk M, Grine L, et al. Validation of a physician global assessment tool for vitiligo extent: results of an international vitiligo expert meeting. *Pigment Cell Melanoma Res*. 2019;32(5):728–33. <https://doi.org/10.1111/pcmr.12784>
- van Geel N, Mook C, Zuidgeest M, Uitentuis SE, Wolkerstorfer A, Speeckaert R. Patients' perception of vitiligo severity. *Acta Derm Venereol*. 2021;101(6):adv00481. <https://doi.org/10.2340/00015555-3823>
- van Geel N, Uitentuis SE, Zuidgeest M, Wolkerstorfer A, Bekkenk MW, Mook C, et al. Validation of a patient global assessment for extent, severity and impact to define the severity strata for the self assessment vitiligo extent score (SA-VES). *J Eur Acad Dermatol Venereol*. 2021;35(1):216–21. <https://doi.org/10.1111/jdv.16562>
- Sosa JJ, Currimbhoy SD, Ukoha U, Sirignano S, O'Leary R, Vandergriff T, et al. Confetti-like depigmentation: a potential sign of rapidly progressing vitiligo. *J Am Acad Dermatol*. 2015;73(2):272–5. <https://doi.org/10.1016/j.jaad.2015.05.014>
- van Geel N, Grine L, De Wispelaere P, Mertens D, Prinsen CAC, Speeckaert R. Clinical visible signs of disease activity in vitiligo: a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol*. 2019;33(9):1667–75. <https://doi.org/10.1111/jdv.15604>
- Zhang L, Chen S, Kang Y, Wang X, Yan F, Jiang M, et al. Association of Clinical Markers with Disease Progression in patients with vitiligo from China. *JAMA Dermatol*. 2020;156(3):288–95. <https://doi.org/10.1001/jamadermatol.2019.4483>
- van Geel N, Passeron T, Wolkerstorfer A, Speeckaert R, Ezzedine K. Reliability and validity of the vitiligo signs of activity score (VSAS). *Br J Dermatol*. 2020;183(5):883–90. <https://doi.org/10.1111/bjd.18950>
- van Geel N, Depaepel L, Vandaele V, Mertens L, van Causenbroeck J, de Schepper S, et al. Assessing the dynamic changes in vitiligo: reliability and validity of the vitiligo disease activity score (VDAS) and vitiligo disease improvement score (VDIS). *J Eur Acad Dermatol Venereol*. 2022;36(8):1334–41. <https://doi.org/10.1111/jdv.18134>
- Ezzedine K, Ahmed M, Tovar-Garza A, Hajj C, Whitton M, Pandya A, et al. Cross-cultural validation of a short-form of the vitiligo impact patient scale (VIPs). *J Am Acad Dermatol*. 2019;81(5):1107–14. <https://doi.org/10.1016/j.jaad.2019.02.008>
- Salzes C, Abadie S, Seneschal J, Whitton M, Meurant JM, Jouary T, et al. The vitiligo impact patient scale (VIPs): development and validation of a vitiligo burden assessment tool. *J Invest Dermatol*. 2016;136(1):52–8. <https://doi.org/10.1038/JID.2015.398>
- Lilly E, Lu PD, Borovicka JH, Victorson D, Kwasny MJ, West DP, et al. Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). *J Am Acad Dermatol*. 2013;69(1):e11–8. <https://doi.org/10.1016/j.jaad.2012.01.038>
- Gupta V, Sreenivas V, Mehta M, Khaitan BK, Ramam M. Measurement properties of the vitiligo impact Scale-22 (VIS-22), a vitiligo-specific quality-of-life instrument. *Br J Dermatol*. 2014;171(5):1084–90. <https://doi.org/10.1111/bjd.13093>
- Picardo M, Huggins RH, Jones H, Marino R, Ogunsoola M, Seneschal J. The humanistic burden of vitiligo: a systematic literature review of

- quality-of-life outcomes. *J Eur Acad Dermatol Venereol.* 2022;2:1507–23. <https://doi.org/10.1111/jdv.18129>
33. Chernyshov PV, Tomas-Aragones L, Manolache L, Pustisek N, Salavastru CM, Marron SE, et al. Quality of life measurement in vitiligo. Position statement of the European academy of dermatology and venereology task force on quality of life and patient oriented outcomes with external experts. *J Eur Acad Dermatol Venereol.* 2023;37(1):21–31. <https://doi.org/10.1111/jdv.18593>
  34. Mulekar SV, Al Eisa A, Delvi MB, Al Issa A, Al Saeed AH. Childhood vitiligo: a long-term study of localized vitiligo treated by noncultured cellular grafting. *Pediatr Dermatol.* 2010;27(2):132–6. <https://doi.org/10.1111/j.1525-1470.2009.00978.x>
  35. Esmat SM, Bassiouny D, Hegazy R, Shalaby S, Ragab N, Ibrahim S, et al. Early localized vitiligo, a medical emergency: long-term follow-up study. *Dermatol Ther.* 2022;35(2):e15219. <https://doi.org/10.1111/dth.15219>
  36. van Geel NAC, Mollet IG, De Schepper S, Tjin EPM, Vermaelen K, Clark RA, et al. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. *Pigment Cell Melanoma Res.* 2010;23(3):375–84. <https://doi.org/10.1111/j.1755-148X.2010.00703.x>
  37. Gan EY, Eleftheriadou V, Esmat S, Hamzavi I, Passeron T, Böhm M, et al. Repigmentation in vitiligo: position paper of the vitiligo global issues consensus conference. *Pigment Cell Melanoma Res.* 2017;30(1):28–40. <https://doi.org/10.1111/pcmr.12561>
  38. Brazzelli V, Antoninetti M, Palazzini S, Barbagallo T, De Silvestri A, Borroni G. Critical evaluation of the variants influencing the clinical response of vitiligo: study of 60 cases treated with ultraviolet B narrow-band phototherapy. *J Eur Acad Dermatol Venereol.* 2007;21(10):1369–74. <https://doi.org/10.1111/j.1468-3083.2007.02278.x>
  39. Shourick J, Ahmed M, Seneschal J, Passeron T, Andreux N, Qureshi A, et al. Development of a shared decision-making tool in vitiligo: an international study. *Br J Dermatol.* 2021;185(4):787–96. <https://doi.org/10.1111/bjd.20137>
  40. Passeron T, Ostovari N, Zakaria W, Fontas E, Larrouy JC, Lacour JP, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. *Arch Dermatol.* 2004;140(9):1065–9. <https://doi.org/10.1001/archderm.140.9.1065>
  41. Westerhof W, Nieuweboer-Krobotova L, Mulder PG, Glazenburg EJ. Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. *Arch Dermatol.* 1999;135(9):1061–6. <https://doi.org/10.1001/archderm.135.9.1061>
  42. Lee JH, Kwon HS, Jung HM, Lee H, Kim GM, Yim HW, et al. Treatment outcomes of topical Calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis. *JAMA Dermatol.* 2019;155(8):929–38. <https://doi.org/10.1001/jamadermatol.2019.0696>
  43. Bae JM, Yoo HJ, Kim H, Lee JH, Kim GM. Combination therapy with 308-nm excimer laser, topical tacrolimus, and short-term systemic corticosteroids for segmental vitiligo: a retrospective study of 159 patients. *J Am Acad Dermatol.* 2015;73(1):76–82. <https://doi.org/10.1016/j.jaad.2015.04.008>
  44. Pandya AG, Harris JE, Leibold M, Hamzavi IH, Butler K, Kuo FI, et al. Addition of narrow-band ultraviolet light B (UVB) phototherapy to Ruxolitinib cream in patients with vitiligo. *J Invest Dermatol.* 2022;142:3352–3355.e4. <https://doi.org/10.1016/j.jid.2022.05.1093>
  45. Middelkamp-Hup MA, Bos JD, Rius-Diaz F, Gonzalez S, Westerhof W. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. *J Eur Acad Dermatol Venereol.* 2007;21(7):942–50. <https://doi.org/10.1111/j.1468-3083.2006.02132.x>
  46. Fontas E, Montaudie H, Passeron T. Oral gliadin-protected superoxide dismutase in addition to phototherapy for treating non-segmental vitiligo: a 24-week prospective randomized placebo-controlled study. *J Eur Acad Dermatol Venereol.* 2021;35(8):1725–9. <https://doi.org/10.1111/jdv.17331>
  47. Jung HM, Jung YS, Lee JH, Kim GM, Bae JM. Antioxidant supplements in combination with phototherapy for vitiligo: a systematic review and metaanalysis of randomized controlled trials. *J Am Acad Dermatol.* 2021;85(2):506–8. <https://doi.org/10.1016/j.jaad.2018.10.010>
  48. Radakovic-Fijan S, Fürsinn-Friedl AM, Hönigsmann H, Tanew A. Oral dexamethasone pulse treatment for vitiligo. *J Am Acad Dermatol.* 2001;44(5):814–7. <https://doi.org/10.1067/mjd.2001.113475>
  49. Nicolaïdou E, Antoniou C, Stratigos AJ, Stefanaki C, Katsambas AD. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. *J Am Acad Dermatol.* 2007;56(2):274–8. <https://doi.org/10.1016/j.jaad.2006.09.004>
  50. Cavalié M, Ezzedine K, Fontas E, Montaudie H, Castela E, Bahadoran P, et al. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. *J Invest Dermatol.* 2015;135(4):970–4. <https://doi.org/10.1038/jid.2014.527>
  51. Nguyen S, Chuah SY, Fontas E, Khemis A, Jhingan A, Thng STG, et al. Atorvastatin in combination with narrowband UV-B in adult patients with active vitiligo: a randomized clinical trial. *JAMA Dermatol.* 2018;154(6):725–6. <https://doi.org/10.1001/jamadermatol.2017.6401>
  52. Tovar-Garza A, Hinojosa JA, Hynan LS, Pandya AG. Addition of oral minipulse dexamethasone to narrowband ultraviolet B phototherapy and topical steroids helps arrest disease activity in patients with vitiligo. *Br J Dermatol.* 2019;180(1):193–4. <https://doi.org/10.1111/bjd.17150>
  53. Esmat SM, El-Mofty M, Rasheed H, Mostafa WZ, Anbar TS, Abdallah M, et al. Efficacy of narrow band UVB with or without OMP in stabilization of vitiligo activity in skin photo-types (III–V): a double-blind, randomized, placebo-controlled, prospective, multicenter study. *Photodermatol Photoimmunol Photomed.* 2022;38(3):277–87. <https://doi.org/10.1111/phpp.12749>
  54. Lommerts JE, Njoo MD, de Rie MA, Wolkerstorfer A, Bekkenk MW. Twenty-year follow-up using a postal survey of childhood vitiligo treated with narrowband ultraviolet B phototherapy. *Br J Dermatol.* 2017;177(3):e60–1. <https://doi.org/10.1111/bjd.15337>
  55. Gill BS, Brar MS, Chaudhary N, Randhawa A. Non-cultured melanocyte transfer in the management of stable vitiligo. *J Family Med Prim Care.* 2019;8(9):2912–6. [https://doi.org/10.4103/jfmpc.jfmpc\\_546\\_19](https://doi.org/10.4103/jfmpc.jfmpc_546_19)
  56. Löntz W, Olsson MJ, Moellmann G, Lerner AB. Pigment cell transplantation for treatment of vitiligo: a progress report. *J Am Acad Dermatol.* 1994;30(4):591–7. [https://doi.org/10.1016/s0190-9622\(94\)70067-2](https://doi.org/10.1016/s0190-9622(94)70067-2)
  57. Verma SB. Vitiligo precipitated by striae: a little known entity. *J Eur Acad Dermatol Venereol.* 2009;23(3):357–8. <https://doi.org/10.1111/j.1468-3083.2008.02844.x>
  58. Park KY, Kwon HJ, Wie JH, Lee HH, Cho SB, Kim BJ, et al. Pregnancy outcomes in patients with vitiligo: a nationwide population-based cohort study from Korea. *J Am Acad Dermatol.* 2018;79(5):836–42. <https://doi.org/10.1016/j.jaad.2018.02.036>
  59. Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. *Cochrane Database Syst Rev.* 2015;2015:CD007346. <https://doi.org/10.1002/14651858.CD007346.pub3>

**How to cite this article:** van Geel N, Speeckaert R, Taïeb A, Ezzedine K, Lim HW, Pandya AG, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part I: towards a new management algorithm. *J Eur Acad Dermatol Venereol.* 2023;37:2173–2184. <https://doi.org/10.1111/jdv.19451>